References
- Sankaran SK. Osteoporosis prevention and treatment. Pharmacological management and treatment implications. Drugs Aging 1996; 9: 472-477. https://doi.org/10.2165/00002512-199609060-00009
- Schneider DL. Management of osteoporosis in geriatric populations. Curr Osteoporos Rep 2008; 6: 100-107. https://doi.org/10.1007/s11914-008-0018-4
- Miller PD. Anti-resorptives in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008; 22: 849-868. https://doi.org/10.1016/j.beem.2008.07.004
- Sibilia V and Netti C. Current therapies and future directions in osteoporosis management. Pharmacol Res 1996; 34: 237-245. https://doi.org/10.1006/phrs.1996.0094
- Han JY, Fan JY, Horie Y et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacol Ther 2008; 117: 280-295. https://doi.org/10.1016/j.pharmthera.2007.09.008
- Hu S, Chen SM, Li XK et al. Antitumor effects of chishen extract from Salvia miltiorrhiza and Paeoniae radix on human hepatocellular carcinoma cells. Acta Pharmacol Sin 2007; 28: 1215-1223. https://doi.org/10.1111/j.1745-7254.2007.00606.x
- Guo BL, Feng YX and Zhao YJ. Review of germplasm resources studies on Salvia miltiorrhiza. Zhongguo ZhongYao ZaZhi 2002; 27: 492-495.
- Chae HJ, Chae SW, Yun DH et al. Prevention of bone loss in ovariectomized rats: the effect of Salvia miltiorrhiza extracts. Immunopharmacol Immunotoxicol 2004; 26: 135-144. https://doi.org/10.1081/IPH-120029951
- Kwak HB, Yang D, Ha H et al. Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1. Exp Mol Med 2006; 38: 256-264. https://doi.org/10.1038/emm.2006.31
- Kwak HB, Sun HM, Ha H et al. Tanshinone IIA suppresses inflammatory bone loss by inhibiting the synthesis of prostaglandin E2 in osteoblasts. Eur J Pharmacol 2008 28; 601: 30-37.
- Kim HK, Woo ER, Lee HW et al. The correlation of Salvia miltiorrhiza extract-induced regulation of osteoclastogenesis with the amount of components tanshinone I, tanshinone IIA, cryptotanshinone, and dihydrotanshinone. Immunopharmacol Immunotoxicol 2008; 30: 347-364. https://doi.org/10.1080/08923970801949133
- Gao Y, He L, Katsumi H et al. Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int J Pharm 2008; 359: 70-78. https://doi.org/10.1016/j.ijpharm.2008.03.016
- Chae HJ, Lee GY, Yang SK et al. Effect of high molecular weight water-soluble chitosan on the trabecular bone and thickness in ovariectomized rats. Immunopharmacol Immunotoxicol 2007; 29: 439-449. https://doi.org/10.1080/08923970701691140
- Lee JY, Choo JE, Choi YS et al. Effect of immobilized cell-binding peptides on chitosan membranes for osteoblastic differentiation of mesenchymal stem cells. Biotechnol Appl Biochem 2009; 52: 69-77. https://doi.org/10.1042/BA20070169
- Yamada S, Ohara N and Hayashi Y. Mineralization of matrix vesicles isolated from a human osteosarcoma cell line in culture with water-soluble chitosan-containing medium. J Biomed Mater Res A. 2003; 66(3):500-506.
- Nagasaka S, Sugimoto H, Nakamura T et al. Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 1997; 47: 215-221. https://doi.org/10.1046/j.1365-2265.1997.2401045.x
- Zaidi M, Davies TF, Zallone A et al. Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep 2009; 7: 47-52. https://doi.org/10.1007/s11914-009-0009-0
- Kalu DN, Liu CC, Hardin RR et al. The aged rat model of ovarian hormone deficiency bone loss. Endocrinology 1989; 124: 7-16. https://doi.org/10.1210/endo-124-1-7
- Chlebowski RT, Kuller LH, Prentice RL et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360(6):573-587. https://doi.org/10.1056/NEJMoa0807684
- Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55(2):103-115. https://doi.org/10.1016/j.maturitas.2006.05.004